ToPCaP

King's Health Partners

King's Health Partners

King’s Health Partners is one of the UK’s five Academic Health Sciences Centres. It brings together a world leading research led university (King’s College London) and three successful NHS Foundation Trusts (Guy’s and St Thomas’, King’s College Hospital and South London and Maudsley).

As an Academic Health Sciences Centre with access to the excellent clinical research facilities of the NIHR Biomedical Research Centre at Guy’s and St Thomas’ and King’s College London, King’s Health Partners is well placed to contribute to prostate cancer research and provides an excellent multidisciplinary research platform for translational research. These centres promote collaboration, and benefit from high levels of creativity, technical innovation, and managerial skill. We can provide applied research that transforms discoveries from fundamental laboratory, clinical, or population-based research into new medical applications such as new drugs or population interventions. Moreover, our translational research also incorporates feedback from the urology centre and prostate cancer clinics so that new clinical applications, such as new biomarkers of prostate cancer risk, can be accurately evaluated.

Our Prostate Cancer Research Network is a multidisciplinary network of clinicians and scientists, representing the fields of epidemiology, clinical medicine, cancer care, cell and molecular biology and immunology. The Network is coordinated by Dr Mieke Van Hemelrijck and Prof Lars Holmberg from the Cancer Epidemiology Group of King’s College London.

One of the main collaborators in our Network are the Urology Centre and Oncology Department of Guy’s Hospital, which are one of the busiest prostate cancer services in the UK with a large team of expertly trained surgeons, oncologists and nurses who look after thousands of prostate cancer patients each year. Our patient population is of particular interest as it includes a large proportion of men at high risk and patients with symptomatic disease as well as a variety of ethnic groups.

Prostate Cancer Clinical Database

A common requirement for all translational and clinical research on prostate cancer is the use of an outstanding registry that contains demographic information about the prostate cancer patient as well as the clinical characteristics of the prostate tumour, the treatment, and access to prostate tissue and blood samples. We are currently setting up such a prostate cancer registry as it allows all clinicians and research scientists involved in prostate cancer research vital access to data and clinical specimens from our patients.

This Prostate Cancer Clinical Database is one of the main tasks of our Prostate Cancer Research Network. In addition to retrospective data collected between 1990 and 2011, covering about 5,000 prostate cancer patients, we also aim to collect information on about 4,000 newly diagnosed men over the next five years.

Our Prostate Cancer Clinical Database is coordinated by a dedicated database manager, Miss Aida Santaolalla, who is working closely with our very experienced urologists. Together with their colleagues they are providing the team with all the clinical information to set up the linkage between prostate tissue, blood samples, and patient-specific data.

For further information about King’s Health Partners http://www.kingshealthpartners.org/